In-hospital medications
| All patients (n=1252) | CAD (n=124) | No CAD (n=1128) | Difference (95% CI) | |
| ACE inhibitors | 160 (12.8%) | 25 (20.2%) | 135 (12.0%) | 8.2 (2.0 to 14.4) |
| ARBs | 156 (12.5%) | 19 (15.3%) | 137 (12.1%) | 3.2 (−3.0 to 9.3) |
| β-blockers | 380 (30.4%) | 92 (74.2%) | 288 (25.5%) | 48.7 (40.6 to 56.8) |
| Aspirin | 239 (19.1%) | 113 (91.1%) | 126 (11.2%) | 80 (74.2 to 85.8) |
| Clopidogrel | 31 (2.5%) | 16 (12.9%) | 15 (1.3%) | 11.6 (8.8 to 14.4) |
| Ticagrelor/prasugrel | 6 (0.5%) | 6 (4.8%) | 0 (0.0%) | 4.8 (3.6 to 6.1) |
| Warfarin | 41 (3.3%) | 5 (4.0%) | 36 (3.2%) | 0.8 (−2.5 to 4.1) |
| NOAC | 29 (2.3%) | 5 (4.0%) | 24 (2.1%) | 1.9 (−0.9 to 4.7) |
| Darunavir/ritonavir | 958 (76.5%) | 61 (49.2%) | 897 (79.5%) | −30.3 (−38.0 to −22.6) |
| Remdesevir | 9 (0.7%) | 0 (0.0%) | 9 (0.8%) | −0.8 (−2.4 to 0.8) |
| Lopinavir/ritonavir | 87 (6.9%) | 27 (21.8%) | 60 (5.3%) | 16.5 (11.8 to 21.1) |
| Levofloxacin | 597 (47.7%) | 42 (33.9%) | 555 (49.2%) | −15.3 (−24.6 to −6.1) |
| Other antibiotics | 555 (44.3%) | 63 (50.8%) | 492 (43.6%) | 7.2 (−2.0 to 16.4) |
| Tocilizumab | 23 (1.8%) | 2 (1.6%) | 21 (1.9%) | −0.2 (−2.7 to 2.2) |
| Hydroxychloroquine | 996 (79.6%) | 87 (70.2%) | 909 (80.6%) | −10.4 (−17.9 to −3.0) |
| Steroids | 763 (60.9%) | 76 (61.3%) | 687 (60.9%) | 0.4 (−8.7 to 9.4) |
| Enoxaparin | 723 (57.8%) | 78 (63.4%) | 645 (57.2%) | 6.2 (−3.0 to 15.4) |
| Hydration | 852 (68.1%) | 84 (67.7%) | 768 (68.1%) | −0.3 (−9.0 to 8.3) |
| Oxygen therapy | 1049 (83.8%) | 101 (81.5%) | 948 (84.0%) | −2.6 (−9.4 to 4.3) |
ACE, angiotensin-converting enzyme; ARBs, angiotensin-receptor blockers; CAD, coronary artery disease; NOAC, novel oral anticoagulant.